Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy

Asako Kitahara; Akinori Ebihara; Shohei Obayashi; Yukihiro Horio; Yoshitaka Ono; Tomohiro Yoshikawa; Naoki Okada; Jun Tanaka; Hiroto Takiguchi; Naoki Hayama; Yoko Ito; Tsuyoshi Oguma; Ichiro Kuwahira; Koichiro Asano

doi:10.2169/internalmedicine.8928-21

CASE REPORTS

Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy

Asako Kitahara, Akinori Ebihara, Shohei Obayashi, Yukihiro Horio, Yoshitaka Ono, Tomohiro Yoshikawa, Naoki Okada, Jun Tanaka, Hiroto Takiguchi, Naoki Hayama, Yoko Ito, Tsuyoshi Oguma, Ichiro Kuwahira, Koichiro Asano

Author information

Asako Kitahara
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Akinori Ebihara
Division of Pulmonary Medicine, Department of Medicine, Tokai University Tokyo Hospital, Japan
Shohei Obayashi
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Yukihiro Horio
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Yoshitaka Ono
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Tomohiro Yoshikawa
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Naoki Okada
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Jun Tanaka
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Hiroto Takiguchi
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Naoki Hayama
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Yoko Ito
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Tsuyoshi Oguma
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
Ichiro Kuwahira
Division of Pulmonary Medicine, Department of Medicine, Tokai University Tokyo Hospital, Japan
Koichiro Asano
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan

Keywords: febrile neutropenia, granulocyte colony-stimulating factor, immune-checkpoint inhibitor, severe acute respiratory syndrome coronavirus 2, tumor regression

JOURNAL OPEN ACCESS

2022 Volume 61 Issue 8 Pages 1219-1223

DOI https://doi.org/10.2169/internalmedicine.8928-21

Browse “Advance online publication” version

Details

Abstract

A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-stimulating factor (G-CSF) was administered until the recovery of neutropenia, when he developed a high fever, severe hypoxemia, and hypotension accompanied by consolidation in the bilateral lungs. His conditions promptly improved after treatment including hydrocortisone and the primary and metastatic tumors remained regressed for 10 months without further treatment. Post-COVID-19 organizing pneumonia during cancer immunochemotherapy can be aggravated by immune-checkpoint inhibitors and G-CSF.

Corresponding author

Register with J-STAGE for free!